Celebrating Diversity Within the Sickle Cell Community: Commitment, Innovation, Practice
avatar for Kenneth R. Bridges

Kenneth R. Bridges

Global Blood Therapeutics
Clinical Scientist
Dr. Kenneth R. Bridges received the MD degree from Harvard Medical School, and subsequently trained
in internal medicine and hematology in Boston, at Massachusetts General and Brigham and Women’s
Hospitals, respectively. Following medical subspecialty training, Dr. Bridges worked on the biology of
cellular iron metabolism for three years at the National Institutes of Health in Bethesda, Maryland. Dr.
Bridges returned to Harvard as a member of the Hematology Division at Brigham and Women’s Hospital
where he achieved the faculty rank of Associate Professor of Medicine. In parallel with his laboratory
investigation of iron metabolism, Dr. Bridges maintained active clinical work and established the Joint
Center for Sickle Cell and Thalassemic Disorders at Brigham and Women’s Hospital and Massachusetts
General Hospital, emphasizing bench-to-patient translational research. Dr. Bridges published over 70
peer-reviewed articles during his academic career, as well as number book chapters. He also co-authored
with Dr. Howard Pearson of Yale University a textbook on red cell disorders and anemia. Dr. Bridges left
academia to work in biotechnology, initially with Hoffman La Roche followed by 3 years at Amgen
where he worked on Aranesp and participated in the launch of Nplate. Dr. Bridges moved to Onyx
Pharmaceuticals where he oversaw several trials involving Kyprolis (carfilzomib) for the treatment of
multiple myeloma. Following the Amgen acquisition of Onyx, Dr. Bridges moved to Global Blood
Therapeutics in the role of Vice President, Medical Affairs working on the new treatment for sickle cell
disease, voxelotor (formerly GBT440).